Month: September 2020

Cellastim S – Reconstitution Application Note

By

Workflow Summary: Human serum albumin (HSA) has been identified as a powerful tool for the expansion of many cell types in vitro [1]. HSA is a multifaceted protein capable of binding many different types of molecules [2]. HSA therefore plays diverse roles in cell biology, acting as an antioxidant to improve health of cells by binding to reactive …

Cellastim S – Optimizing Antibody Production in Animal-Free Media with the Supplementation of Recombinant Human Albumin

By

Abstract Due to the increased risk of transmitting infectious agents, antibody production is moving away from the use of animal-derived components in bioproduction. The switch to animal-free cell culture media often results in less performance which is evident in longer doubling time, lower peak cell density and reduced antibody titer. We evaluated recombinant human albumin …

Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease

By

Abstract The measurement of the electrophysiology of human pluripotent stem cell-derived cardiomyocytes is critical for their biomedical applications, from disease modeling to drug screening. Yet, a method that enables the high-throughput intracellular electrophysiology measurement of single cardiomyocytes in adherent culture is not available. To address this area, we have fabricated vertical nanopillar electrodes that can …

Solving the Vaccine Supply Challenge

By

Right now is an exciting time for vaccine science, with an unprecedented level of attention, resources, and testing being directed at the effort to control the COVID-19 pandemic. In this post, we share a new video and provide additional information to explain the role that InVitria’s recombinant human protein products play in accelerating the vaccine …

Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times

By

 ICELLIS BIOREACTOR BACKGROUND In the past five years, Pall’s iCELLis bioreactor has emerged as the leading bioreactor technology for clinical and commercial manufacturing of viral vectors and vaccines, with the following data reported in peer- reviewed publications.   Single-use, fixed-bed bioreactor Cell substrate composed of medical grade, uncoated, uncharged polyethylene teraphalate (PET) carriers Closed system …